Skip to main content

Table 3 Pregnancy outcomes of women enrolled in the CAPRISA 002 Study, KwaZulu-Natal Province (2004–2019)a

From: Pregnancy rates and outcomes in a longitudinal HIV cohort in the context of evolving antiretroviral treatment provision in South Africa

 

HIV negative

( N  = 25 pregnancies –21 with known outcomes)b

HIV infection, ART naïve

( N  = 70 pregnancies –68 with known outcomes) c,d

HIV infection on ART

( N  = 74 –66 with known outcomes) e,f

Full term live birth > 37 weeks

(n, %)

15 (71.4)

53 (77.9)

50 (75.8)

Delivery method

NVD = 2 (13.3)

NVD = 30 (56.6)

NVD = 28 (56.0)

C-section = 3 (20)

C-section = 21 (39.6)

C-section = 20 (40.0)

Unknown = 10 (66.7)

Unknown = 2 (3.8)

Unknown = 2(4.0)

Premature live birth < 37 weeks

(n, %)

4 (19.0)

6 (8.8)

7 (10.6)

Delivery method

Unknown = 4

NVD = 3

C-section = 3

NVD = 4

C-section = 3

Spontaneous fetal death and/or still birth > 20 weeks (n, %)

1 (4.8)

1 (1.4)

1 (1.5)

Spontaneous miscarriage < 20 weeks (n, %)

0

4 (5.9)

4 (6.1)

Therapeutic/elective miscarriage (n, %)

1 (4.8)

4 (5.9)

4 (6.1)

Other adverse birth outcomesg

0

4 (5.9)

6 (9.1)

ART in pregnancy

 MTCT prophylaxis (single or dual drug regimens) (n, %)

3 (12.0)

23 (32.9)

0

 ART (n, %)

1 (4.0)

36 (51.4)

74 (100.0)

 None (n, %)

21 (84.0)

11 (15.7)

0

 Median months on ART prior to delivery (IQR)

-

5 (4—6)h

26 (16.5 – 47.0)i

 Median months on ART prior to falling pregnant (IQR)

-

-

22 (12.0—40.0)

HIV mother-to-child transmission events

 

-

4 (5.9)

2 (3.0)

Laboratory evaluations closer to delivery

 Median CD4 prior to delivery (IQR), cell/µL

-

534 (407—652)

616 (450—753)

 Detectable HIV VL (n, %)

-

30 (50.8)

10 (18.2)

 Undetectable HIV VL

(<400 copies/ml) (n, %)

-

29 (49.2)

45 (81.8)

 Mean haemoglobin prior to delivery

(SD), g/dl

-

11.0 (1.2)

11.7 (1.6)

Bacterial vaginosis and STIs diagnosed before or during pregnancy in women with a full-term live birth or a premature live birth outcomej (n, %)

 Bacterial vaginosis

16 (84.2)

47 (87.0)

47 (88.7)

 Chlamydia trachomatis

7 (36.8)

18 (33.3)

23 (43.4)

 Herpes Simplex Virus (HSV) type 2

2 (10.5)

18 (33.3)

9 (17.0)

 Mycoplasma genitalium

2 (10.5)

22 (40.7)

19 (35.8)

 Neisseria gonorrhoeae

4 (21.1)

9 (16.7)

12 (22.6)

 Trichomonas vaginalis

7 (36.8)

24 (44.4)

19 (35.8)

  1. a Includes 13 repeat pregnancies in each study phase
  2. b 4 outcome unknown
  3. c 2 outcome unknown
  4. d missing HIV VL in 9 participants
  5. e 5 still pregnant and 3 reached end of study before delivery
  6. f missing HIV VL in 11 participants
  7. g includes 7 early neonatal deaths, 1 low birth weight, 1 meconium aspiration,1 breech presentation with shoulder injury
  8. h for 33 women who delivered after ART initiation
  9. i for 61 women with outcomes
  10. j only the first pregnancy in each phase was considered. Out of all the 156 first pregnancies in each study phase combined, 126 full-term and pre-term birth outcomes were recorded. Therefore, denominators used were N = 19, N = 54 and N = 53
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us